Inhibition or genetic deletion of P2X7 reverses this polarization, enhances inflammatory gene expression, and restores checkpoint inhibitor responsiveness in NSCLC models, highlighting the P2X7/STAT6 pathway as a mechanistic barrier to successful immunotherapy (100). This evidence concerns the gene P2RX7 and non-small cell lung carcinoma.